CALGARY, June 13 /CNW/ - SemBioSys Genetics Inc. (TSX:SBS), a
biotechnology company developing a broad pipeline of protein-based
pharmaceuticals and non-pharmaceutical products, today announced an agreement
to acquire technology assets and in-license intellectual property related to
the manufacture of biopharmaceuticals in safflower from Syngenta Crop
Protection AG. The assets and intellectual property will allow SemBioSys to
further increase its efficiency in the development of transgenic safflower by
shortening the time it takes to develop safflower plants producing the desired
pharmaceutical protein.
